Greenphire Appoints Chief Commercial Officer
News Jul 12, 2012
Greenphire has announced the appointment of John M Blakeley to the role of Chief Commercial Officer.
Blakeley will lead Greenphire’s global marketing and sales strategy as the company continues to extend the adoption of its clinical payment technology platforms, the ClinCard System and the eClinicalGPS, to the pharmaceutical, medical device, and contract research markets.
Prior to joining Greenphire, Blakeley spent 10 years in senior management and executive roles at clinical service and medical device provider ERT, most recently serving as ERT’s Chief Commercial Officer.
“Greenphire is truly a rising star in our industry, unlike almost any young clinical technology company we’ve seen in the last decade,” said Blakeley.
Blakeley continued, “The team is motivated and savvy, and the technologies they’ve developed shift the global clinical payment paradigm on the same scale that EDC, IVR and ePRO have done for clinical data in years past. It’s a thrill for me, both professionally and personally, to continue to be at the cutting edge of technological innovation which will ultimately make drug development and medical discovery less expensive and more efficient.”
Greenphire CEO Sam Whitaker reciprocated Blakeley’s comment and shared his optimism with regards to the company’s future.
“John’s track record speaks for itself,” he said. “When John started at ERT it was still a relatively early-stage company, and the vision and leadership he exhibited in bringing clinical solutions to a global market is a model for any young company in our industry. John is an exemplary leader and an innovative thinker, and the Greenphire team is excited to work with him to further establish Greenphire as a pillar in the clinical research industry and the leader in clinical payment technologies.”
An immunotherapeutic antibody therapy re-educates macrophages to activate passivated cytotoxic T cells to kill cancer. The antibody therapy prevented the growth of tumors in several mouse models. The development of the therapy has now progressed to patient testing in a phase I/II clinical trial.READ MORE
15th International Conference on Surgical Pathology and Cancer Diagnosis
Apr 15 - Apr 16, 2019